Challenges and opportunities in designing clinical trials for neuromyelitis optica

Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Weinshenker, Brian G., Barron, Gerard, Behne, Jacinta M., Bennett, Jeffery L., Chin, Peter S., Cree, Bruce A.C., de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T., Palace, Jacqueline, Smith, Terry J., Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K., Wasiewski, Warren, Wingerchuk, Dean M., Yeaman, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Views & Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424131/
https://ncbi.nlm.nih.gov/pubmed/25841026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000001520
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados